Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase i inhibitors

Journal of Antibiotics

Volumn 68, Issue 4, 2014, Pages 271-278

  Siricilla, Shajila ^a   Mitachi, Katsuhiko ^a   Wan, Bajoie ^b   Franzblau, Scott G ^b   Kurosu, Michio ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [CARBAMOYL[5 (2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YL) 3,4 DIMETHOXY TETRAHYDRO- FURAN 2 YL]METHOXY] 4,5 DIHYDROXY 5,6 DIHYDRO 4H PYRAN 2 CARBOXYLIC ACID(2 OXO AZEPAN 3 YL)AMIDE; 6 [CARBAMOYL[5 (2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YL) 4 HYDROXY 3 METHOXY TETRAHYDRO FURAN 2 YL] METHOXY] 4,5 DIHYDROXY 5,6 DIHYDRO 4H PYRAN 2 CARBOXYLIC ACID(2 OXO AZEPAN 3 YL)AMIDE; 6 [CARBAMOYL[5 (2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YL) 4 HYDROXY 3 METHOXY TETRAHYDRO FURAN 2 YL]METHOXY] 4,5 DIHYDROXY 5,6 DIHYDRO 4H PYRAN 2 CARBOXYLIC ACID(3,4 DIFLUORO PHENYL)AMIDE; BACTERIAL ENZYME; BACTERICIDE; ETHAMBUTOL; ISONIAZID; OXYGEN; RNA POLYMERASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UT 01309; AMINOGLYCOSIDE; BACTERIAL PROTEIN; CAPROLACTAM; CAPURAMYCIN; DNA DIRECTED RNA POLYMERASE; ENZYME INHIBITOR; MRAY PROTEIN, BACTERIA; SQ-641; TRANSFERASE; URIDINE; UT-01320;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CAPROLACTAM; DNA-DIRECTED RNA POLYMERASES; DRUG SYNERGISM; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXYGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERASES; URIDINE;

EID: 84928782725     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.133     Document Type: Article

References (42)

1. Nakanjako, D. et al. Tuberculosis and human immunodeficiency virus co-infections and their predictors at a hospital-based HIV/AIDS clinic in Uganda. Int. J. Tuberc. Lung Dis. 14, 1621-1628 (2010).
2. Diedrich, C. R., Flynn, J. L. HIV-1/Mycobacterium tuberculosis co-infection immunology: How does HIV-1 exacerbate tuberculosis? Infect. Immun. 79, 1407-1417 (2011).
3. Chien, J. Y. et al. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. J. Antimicrob. Chemother. 68, 1910-1916 (2013).
4. Ranjbar, S. et al. HIV-1 Replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLoS ONE 4, e6116 (2009).
5. Connolly, L. E., Edelstein, P. H., Ramakrishnan, L. Why is long-term therapy required to cure tuberculosis? PLoS Med. 4, 435-442 (2003).
6. Miranda, M. S., Breiman, A., Allain, S., Deknuydt, F., Altare, F. The tuberculous granuloma: an unsuccessful host defense mechanism providing a safety shelter for the bacteria? Clin. Develop. Immun. 2012, 1-14 (2012).
7. Wayne, L. G., Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 2062-2069 (1996).
8. Claudia, S. et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54, 4150-4158 (2010).
9. van Heijenoort, J. Lipid intermediates in the biosynthesis of bacterial peptidoglycan. Microbiol. Mol. Biol. Rev. 71, 620-635 (2007).
10. Hett, E. C., Rubin, E. J. Bacterial growth and cell division: a Mycobacterial perspective. Microbiol. Mol. Biol. Rev. 72, 126-156 (2008).
11. Barry, C. E., Blanchard, J. S. The chemical biology of new drugs in development for tuberculosis. Curr. Opin. Chem. Biol. 14, 456-466 (2010).
12. Reddy, V. M., Einck, L., Nacy, C. A. In vitro antimycobacterial activity of capuramycin analogs. Antimicro. Agents Chemother. 52, 719-721 (2008).
13. Kurosu, M., Li, K. Synthetic studies towards the identification of novel capuramycin analogs with antimycobacterial activity. Heterocycles 77, 217-225 (2009).
14. Kurosu, M., Li, K., Crick, D. C. A concise synthesis of capuramycin. Org. Lett. 11, 2393-2396 (2009).
15. Wang, Y., Siricilla, S., Aleiwi, B. A., Kurosu, M. Improved synthesis of capuramycin and its analogues. Chem. Eur. J. 19, 13847-13858 (2013).
16. Koga, T. et al. Activity of capuramycin analogs against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellular in vitro and in vivo. J. Antimicro. Chemother. 54, 755-760 (2004).
17. Nikonenko, B. V. et al. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob. Agents Chemother. 53, 3138-3139 (2009).
18. Dubuisson, T. et al. In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria. J. Antimicrob. Chemother. 65, 2590-2597 (2010).
19. Bogatcheva, E. et al. Chemical modification of capuramycins to enhance antibacterial activity. J. Antimicrob. Chemother. 66, 578-587 (2011).
20. Cho, S. H. et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 1380-1358 (2007).
21. Siricilla, S., Mitachi, K., Skorupinska-Tudek, K., Swiezewska, E., Kurosu, M. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I. Anal. Biochem. 461, 36-35 (2014).
22. Wayne, L. G., Sramek, H. A. Antigenic differences between extracts of actively replicating and synchronized resting cells of Mycobacterium tuberculosis. Infect. Immun. 24, 363-370 (1979).
23. Gengenbacher, M., Rao, S. P. S., Pethe, K., Dick, T. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 156, 81-87 (2010).
24. Hsieh, M. H., Chen, M. Y., Victor, L. Y., Chow, J. W. Synergy assessed by checkerboard. A critical analysis. Diagn. Microbiol. Infect. Dis. 16, 343-349 (1993).
25. Meletiadis, J., Pournaras, S., Roilides, E., Walsh, T. J. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, monte carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54, 602-609 (2010).
26. Debnath, J. et al. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J. Med. Chem. 55, 3739-3755 (2012).
27. Levin, M. E., Hatfull, G. F. Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol. Microbiol. 8, 277-285 (1993).
28. Siegmund, V., Santner, T., Micura, R., Marx, A. Screening mutant libraries of T7 RNA polymerase for candidates with increased acceptance of 2'-modified nucleotides. Chem. Commun. 48, 9870-9872 (2012).
29. Kuhlman, P., Duff, H. L., Galant, A. A fluorescence-based assay for multisubunit DNAdependent RNA polymerases. Analy. Biochem. 324, 183-190 (2004).
30. Onodera, K., Kawasaki, T., Kamijo, S. Discovery of novel antimicrobial agents targeting the bacterial RNA polymerase by high-throughput virtual screening. Chem-Bio. Informat. J. 11, 52-62 (2011).
31. Boshoff, H. I. M., Barry, C. E. Tuberculosis - metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70-80 (2005).
32. Ishizaki, Y. et al. Inhibition of the first step in synthesis of the Mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J. Biol. Chem. 288, 30309-30319 (2013).
33. Engohang-Ndong, J. Antimycobacterial drugs currently in phase II clinical trials and preclinical phase for tuberculosis treatment. Expert Opin. Investig. Drugs. 21, 1789-1800 (2012).
34. Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104, 901-912 (2001).
35. Snewin, VA et al. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67, 4586-4593 (1999).
36. Kurosu, M., Mahapatra, S., Narayanasamy, P., Crick, D. C. Chemoenzymatic synthesis of park's nucleotide: toward the development of high-throughput screening for MraY inhibitors. Tetrahedron Lett. 48, 799-803 (2007).
37. Li, K., Kurosu, M. Synthetic studies on Mycobacterium tuberculosis specific fluorescent park's nucleotide probe. Heterocycles 76, 455-469 (2008).
38. Mitachi, K., Mohan, P., Siricilla, S., Kurosu, M. One-pot protection-glycosylation reactions for synthesis of lipid II analogues. Chem. A. Eur. J. 20, 4554-4558 (2014).
39. Mandana, R., Marie-Antoinette, L., Peter, S., Mamadou, D. Breaking down the wall: Fractionation of mycobacteria. J. Microbiol. Methods 68, 32-39 (2007).
40. Bouhss, A., Crouvoisier, M., Blanot, D., Mengin-Lecreulx, D. Purification and characterization of the bacterial MraY translocase catalyzing the first membrane step of peptidoglycan biosynthesis. J. Biol. Chem. 279, 29974-29980 (2004).
41. Burgess, R. R., Jendrisak, J. J. A procedure for the rapid, large-scale purification of Escherichia coli DNA-dependent RNA polymerase involving polymin P precipitation and DNA-cellulose chromatography. Biochemistry 14, 4634-4638 (1975).
42. Ohrt, C., Willingmyre, G. D., Lee, P., Knirsch, C., Milhous, W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46, 2518-2524 (2002).